Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Xuan, Li ^a   Huang, Fen ^a   Fan, Zhiping ^a   Zhou, Hongsheng ^a   Zhang, Xian ^a   Yu, Guopan ^a   Zhang, Yu ^a   Liu, Can ^a   Sun, Jing ^a   Liu, Qifa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Conditioning; Cytomegalovirus; Epstein Barr virus; Hematological malignancies

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; ITRACONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORFLOXACIN; RITUXIMAB; SULFAMETHOXAZOLE; THYMOCYTE ANTIBODY; VIRUS DNA; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLAST CELL CRISIS; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC LYMPHOCYTE; DENDRITIC CELL SARCOMA; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYCOSIS; MYELITIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PLASMACYTOID DENDRITIC CELL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SCHOOL CHILD; VIRUS ENCEPHALITIS; VIRUS PNEUMONIA; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIREMIA; YOUNG ADULT;

EID: 84864444500     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-46     Document Type: Article

References (38)

1. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. C Schmid, M Schleuning, R Schwerdtfeger, B Hertenstein, E Mischak-Weissinger, D Bunjes, SV Harsdorf, C Scheid, U Holtick, H Greinix, F Keil, B Schneider, M Sandherr, G Bug, J Tischer, G Ledderose, M Hallek, W Hiddemann, HJ Kolb, Blood 2006 108 1092 1099 10.1182/blood-2005-10- 4165 16551971 (Pubitemid 44154650)
2. Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. M Lv, X Huang, J Hematol Oncol 2012 5 10 10.1186/1756-8722-5- 10 22424172
3. Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. A Martin-Pena, M Aguilar-Guisado, I Espigado, R Parody, J Miguel Cisneros, Clin Transplant 2011 25 468 474 10.1111/j.1399-0012.2010.01286.x 20482561
4. Novel strategies for relapsed and refractory acute myeloid leukemia. AR Mato, A Morgans, SM Luger, Curr Opin Hematol 2008 15 108 114 10.1097/MOH.0b013e3282f463d2 18300756 (Pubitemid 351323150)
5. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). O Ringden, M Labopin, S Tura, W Arcese, A Iriondo, R Zittoun, J Sierra, NC Gorin, Br J Haematol 1996 93 637 645 10.1046/j.1365-2141.1996.d01-1681.x 8652385 (Pubitemid 26168607)
6. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. S Giralt, PF Thall, I Khouri, X Wang, I Braunschweig, C Ippolitti, D Claxton, M Donato, J Bruton, A Cohen, M Davis, BS Andersson, P Anderlini, J Gajewski, S Kornblau, M Andreeff, D Przepiorka, NT Ueno, J Molldrem, R Champlin, Blood 2001 97 631 637 10.1182/blood.V97.3.631 11157478 (Pubitemid 32113394)
7. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. PA McSweeney, D Niederwieser, JA Shizuru, BM Sandmaier, AJ Molina, DG Maloney, TR Chauncey, TA Gooley, U Hegenbart, RA Nash, J Radich, JL Wagner, S Minor, FR Appelbaum, WI Bensinger, E Bryant, ME Flowers, GE Georges, FC Grumet, HP Kiem, B Torok-Storb, C Yu, KG Blume, RF Storb, Blood 2001 97 3390 3400 10.1182/blood.V97.11.3390 11369628
8. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. G Gurman, M Arat, O Ilhan, N Konuk, M Beksac, H Celebi, M Ozcan, O Arslan, C Ustun, H Akan, A Uysal, H Koc, Cytotherapy 2001 3 253 260 10.1080/146532401317070880 12171713 (Pubitemid 34790198)
9. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. CH Gutierrez-Aguirre, OG Cantu-Rodriguez, O Gonzalez-Llano, R Salazar-Riojas, O Martinez-Gonzalez, JC Jaime-Perez, A Morales-Toquero, LC Tarin-Arzaga, GJ Ruiz-Arguelles, D Gomez-Almaguer, Hematology 2007 12 193 197 10.1080/10245330701214285 17558694 (Pubitemid 46930245)
10. Risk assessment in haematopoietic stem cell transplantation: conditioning. J Aschan, Best Pract Res Clin Haematol 2007 20 295 310 10.1016/j.beha.2006.09.004 17448963 (Pubitemid 46613452)
11. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. D Engelhard, H Elishoov, R Or, E Naparstek, A Nagler, N Strauss, G Cividalli, M Aker, N Ramu, A Simhon, et al. Bone Marrow Transplant 1995 16 565 570 8528173
12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. A Mengarelli, A Iori, C Guglielmi, A Romano, R Cerretti, C Torromeo, A Micozzi, S Fenu, L Laurenti, V Donato, L De Felice, W Arcese, Haematologica 2002 87 52 58 11801465 (Pubitemid 34101113)
13. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. QF Liu, ZP Fan, Y Zhang, ZJ Jiang, CY Wang, D Xu, J Sun, Y Xiao, H Tan, Biol Blood Marrow Transplant 2009 15 1376 1385 10.1016/j.bbmt.2009.06.017 19822296
14. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. YC Liu, PL Lu, HH Hsiao, CS Chang, TC Liu, WC Yang, SF Lin, Ann Hematol 2012 91 587 595 10.1007/s00277-011-1351-8 21997849
15. Definitions of cytomegalovirus infection and disease in transplant recipients. P Ljungman, P Griffiths, C Paya, Clin Infect Dis 2002 34 1094 1097 10.1086/339329 11914998 (Pubitemid 34289682)
16. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. E Meijer, JJ Cornelissen, Curr Opin Hematol 2008 15 576 585 10.1097/MOH.0b013e328311f438 18832928
17. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. QF Liu, ZP Fan, XD Luo, J Sun, Y Zhang, YQ Ding, Transpl Infect Dis 2010 12 284 291 10.1111/j.1399-3062.2010.00502.x 20345506
18. Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation. E Jaskula, D Dlubek, M Sedzimirska, D Duda, A Tarnowska, A Lange, Transplant Proc 2010 42 3273 3276 10.1016/j.transproceed.2010.07.027 20970670
19. The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. H Olkinuora, E von Willebrand, JM Kantele, O Vainio, K Talvensaari, U Saarinen-Pihkala, S Siitonen, K Vettenranta, Scand J Immunol 2011 73 586 593 10.1111/j.1365-3083.2011.02530.x 21323694
20. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. SY Kim, DG Lee, MS Kim, HJ Kim, S Lee, CK Min, Am J Hematol 2008 83 784 788 10.1002/ajh.21227 18661492
21. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. N Reddy, K Rezvani, AJ Barrett, BN Savani, Biol Blood Marrow Transplant 2011 17 591 597 10.1016/j.bbmt.2010.08.007 20732435
22. Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens. M Jimenez, G Ercilla, C Martinez, Leukemia 2007 21 1628 1637 10.1038/sj.leu.2404681 17525730 (Pubitemid 47090130)
23. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. C Junghanss, M Boeckh, RA Carter, BM Sandmaier, MB Maris, DG Maloney, T Chauncey, PA McSweeney, MT Little, L Corey, R Storb, Blood 2002 99 1978 1985 10.1182/blood.V99.6.1978 11877269 (Pubitemid 34525478)
24. Human herpesvirus 6 (HHV-6)-associated pleurisy after unrelated cord blood transplantation in children with chemotherapy-resistant malignant Lymphoma. A Suminoe, A Matsuzaki, Y Koga, K Kusuhara, T Hara, J Pediatr Hematol Oncol 2007 29 709 712 10.1097/MPH.0b013e318142b50d 17921853 (Pubitemid 47549184)
25. Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. RM Peres, CR Costa, PD Andrade, SH Bonon, DM Albuquerque, C de Oliveira, AC Vigorito, FJ Aranha, CA de Souza, SC Costa, BMC Infect Dis 2010 10 147 10.1186/1471-2334-10-147 20515464
26. SH Swerdlow, SA Webber, A Chadburn, JA Ferry, Post-transplant lymphoproliferative disorders. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues IARC Press, Lyon 2008 343 349
27. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. HJ Wagner, CM Rooney, HE Heslop, Biol Blood Marrow Transplant 2002 8 1 8 10.1053/bbmt.2002.v8.pm11846351 11846351 (Pubitemid 34141545)
28. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. J Styczynski, P Reusser, H Einsele, R de la Camara, C Cordonnier, KN Ward, P Ljungman, D Engelhard, Bone Marrow Transplant 2009 43 757 770 10.1038/bmt.2008.386 19043458
29. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. A Kinch, G Oberg, J Arvidson, KI Falk, A Linde, K Pauksens, Scand J Infect Dis 2007 39 235 244 10.1080/00365540600978906 17366054 (Pubitemid 46322808)
30. Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. S Mineishi, WL Longo, ME Atkinson, EP Smith, M Hamielec, SR Wiersma, TJ Kinsella, FG Schuening, Bone Marrow Transplant 1999 23 1217 1222 10.1038/sj.bmt.1701793 10414906 (Pubitemid 29312926)
31. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. M de Lima, A Anagnostopoulos, M Munsell, M Shahjahan, N Ueno, C Ippoliti, BS Andersson, J Gajewski, D Couriel, J Cortes, M Donato, J Neumann, R Champlin, S Giralt, Blood 2004 104 865 872 10.1182/blood-2003-11-3750 15090449 (Pubitemid 38970586)
32. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. KS Peggs, K Thomson, DP Hart, J Geary, EC Morris, K Yong, AH Goldstone, DC Linch, S Mackinnon, Blood 2004 103 1548 1556 14576063 (Pubitemid 38168677)
33. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. P Frere, F Baron, C Bonnet, K Hafraoui, M Pereira, E Willems, G Fillet, Y Beguin, Bone Marrow Transplant 2006 37 411 418 10.1038/sj.bmt.1705255 16415900 (Pubitemid 43250476)
34. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. A Gratwohl, R Brand, F Frassoni, V Rocha, D Niederwieser, P Reusser, H Einsele, C Cordonnier, Bone Marrow Transplant 2005 36 757 769 10.1038/sj.bmt.1705140 16151426 (Pubitemid 41613298)
35. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. H Omar, H Hagglund, A Gustafsson-Jernberg, K LeBlanc, J Mattsson, M Remberger, O Ringden, E Sparrelid, M Sundin, J Winiarski, Z Yun, P Ljungman, Transpl Infect Dis 2009 11 393 399 10.1111/j.1399-3062.2009.00410.x 19497070
36. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. O Landgren, ES Gilbert, JD Rizzo, G Socie, PM Banks, KA Sobocinski, MM Horowitz, ES Jaffe, DW Kingma, LB Travis, ME Flowers, PJ Martin, HJ Deeg, RE Curtis, Blood 2009 113 4992 5001 10.1182/blood-2008-09-178046 19264919
37. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. CG Brunstein, DJ Weisdorf, T DeFor, JN Barker, J Tolar, JA van Burik, JE Wagner, Blood 2006 108 2874 2880 10.1182/blood-2006-03-011791 16804113
38. Epstein-Barr virus-associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation. XL Wu, QF Liu, J Hematol Oncol 2012 5 Suppl 1 8 10.1186/1756-8722-5-S1-A8